一般社団法人日本呼吸器学会 公式サイト
日本呼吸器学会英文誌 Respiratory Investigation
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集

Abstract

Full Text of PDF Full Text of PDF (361k)  required ID / password
Article in Japanese

Case Report

A case of HER2-mutation-positive locally advanced non-small cell lung cancer treated with durvalumab after chemoradiotherapy

Yuko Sasaki  Hisashi Tanaka  Tomonori Makiguchi  Yuri Kobori  Haruka Odagiri  Sadatomo Tasaka 

Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine

ABSTRACT

Consolidation therapy with durvalumab after chemoradiotherapy has been standard treatment for patients with stage III, locally advanced non-small cell lung cancer (NSCLC). However, there have been few reports about its efficacy for patients with driver mutations. Notably, it remains unclear whether durvalumab is effective for patients with locally advanced NSCLC harboring HER2 mutation.
A 65-year-old female was referred to our hospital because of an abnormal shadow on her chest roentgenogram. We made a diagnosis of adenocarcinoma (cT2aN3M0, Stage IIIB) and treated the patient with definitive chemoradiotherapy followed by durvalumab for one year. After 15 months, she developed disease recurrence. After the sixth-line treatment, she died 3 years and 3 months after the start of durvalumab treatment.

KEYWORDS

HER2 exon 20 insertion mutation  Non-small cell lung cancer (NSCLC)  Immune checkpoint inhibitor (ICI)  Durvalumab 

Received 25 May 2022 / Accepted 13 Jul 2022

AJRS, 11(5): 310-314, 2022

Google Scholar